Farmoquimica (IFC-39739)

Countries
  • Brazil
Where the impacts of the investment may be experienced.
Financial Institutions
  • International Finance Corporation (IFC)
International, regional and national development finance institutions. Many of these banks have a public interest mission, such as poverty reduction.
Project Status
Proposed
Bank Risk Rating
B
Risk rating varies among banks and may refer only to the particular investment and not to the risk for the project as a whole. Projects marked 'U' have an 'Unknown' risk rating at the time of disclosure.
Borrower
DIVCOM PHARMA
The holder of the loan, grant, or other investment.
Sectors
  • Education and Health
The service or industry focus of the investment. A project can have several sectors.
Investment Type(s)
Loan
The categories of the bank investment: loan, grant, etc.
Investment Amount (USD)
$ 116.00 million
Value listed on project documents at time of disclosure. If necessary, converted to USD$. Please review updated project documents for more information.
Loan Amount (USD)
$ 116.00 million
Value listed on project documents at time of disclosure. If necessary, converted to USD$. Please review updated project documents for more information.
Project Cost (USD)
$ 116.00 million
Value listed on project documents at time of disclosure. If necessary, converted to USD$. Please see updated project documentation for more information.
Primary Source

Original disclosure @ IFC website

Updated in EWS Nov 14, 2017

Disclosed by Bank Nov 10, 2017


Contribute Information
Can you contribute information about this project?
Contact the EWS Team

Project Description
Farmoquimica or “the company” ( www.fqm.com.br ), is a Brazilian pharmaceutical company selling branded prescription drugs; with a product line that includes more than 50 branded drugs among 9 specialties. The company is fully owned by Laboratorios Roemmers S.A., Argentina's largest pharmaceutical company and #5 player in LAC. The proposed IFC investment includes a loan for a total of up to USD 116 million; including US$31 million from its own account and the balance from syndication. The proposed investment will be used to support the business combination between FQM and Divcom and finance the acquisition of brands commercialized by Divcom. Divcom Pharma ( www1.divcom.com.br/divc/home/index.html) is a medium-sized manufacturer and distributor of Over the Counter (OTC) medicines in Brazil's Northeast (the “project”).
Investment Description
  • International Finance Corporation (IFC)
Contact Information
ACCOUNTABILITY MECHANISM OF IFC The Compliance Advisor Ombudsman (CAO) is the independent complaint mechanism and fact-finding body for people who believe they are likely to be, or have been, adversely affected by an IFC or MIGA- financed project. If you submit a complaint to the CAO, they may assist you in resolving a dispute with the company and/or investigate to assess whether the IFC is following its own policies and procedures for preventing harm to people or the environment. If you want to submit a complaint electronically, you can email the CAO at CAO@worldbankgroup.org. You can learn more about the CAO and how to file a complaint at http://www.cao-ombudsman.org/